Stevens-Johnson syndrome during nivolumab treatment of NSCLC

Ann Oncol. 2018 Jan 1;29(1):283-284. doi: 10.1093/annonc/mdx640.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Agents, Immunological / adverse effects
  • Antineoplastic Agents, Immunological / therapeutic use
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Middle Aged
  • Nivolumab / adverse effects*
  • Nivolumab / therapeutic use
  • Stevens-Johnson Syndrome / etiology*

Substances

  • Antineoplastic Agents, Immunological
  • Nivolumab